These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ ...

Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of ...

The second mechanism whereby wildtype p53 helps the cancer cell proliferate is in suppressing mitochondrial overproduction of reactive oxygen species. This mechanism has been well-demonstrated in ...

Klemp discusses recent progress of the Company's Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also ... avoid multidrug resistance mechanisms and to eliminate the ...

Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, California 93106, United States Biomolecular Science and Engineering Program, University of California ...

The study showed that higher expression of ALDH3A2 was positively correlated with the cytarabine sensitivity value. The study used a combination of the ALDH3A2 inhibitor disulfiram and cytarabine ...